Min Park, MBA

I have the privilege of working with the best Project Managers in the industry. This article offers insights on how our clients and their programs benefit from Samsung Biologics from a project management perspective.

46

1 Comment

As the Founder & CEO of SELLAS Life Sciences Group, Inc., I am often asked what drives our strategy in the high-stakes world of hematology/oncology. Recently, I revisited the classic film ‘Zorba the Greek,” and will watch it with our employees. While many see it as a tale of a free spirit, as a proud Greek-American, I see it as a masterclass in the very traits required to lead a life sciences company. After the film, I found myself reflecting on how the "Zorba Way" translates to the translational research, the boardroom, and the clinic. 1. Risk & Innovation: The "Full Catastrophe" Zorba famously embraces the "full catastrophe" of life. In drug development, innovation is impossible without risk. We don’t shy away from the difficult science; we embrace the complexity of the immune system to find breakthroughs that others might miss - and that’s what we do! 2. Resilience: There is a pivotal scene where a massive timber project collapses. Instead of despairing, Zorba dances. In biotech, trials can be unpredictable - resilience isn't just about surviving failure; it’s about the agility to find a new path forward with even more vigor than before - fortunately, we have not had any clinical setbacks but, after the reverse merger, we had to be smart and resilient to push forward. 3. Passion & Analysis: The film is a tug-of-war between the "Scholar" (analysis) and "Zorba" (passion). Success at SELLAS requires both. We need rigorous, cold-eyed clinical data and molecular analysis—but that data is meaningless without the fire and soul to push through the years of development. 4. Cultural Identity: My heritage teaches me Philotimo—a complex word meaning "love of honor" and doing right by one's community. This cultural anchor drives my personal responsibility to our investors and patients. We aren't just managing tickers and spreadsheets; we are managing the hopes of families. 5. Final Reflection: Leadership is a dance between the known and the unknown. My commitment to our investors and patients is this: we will remain analytical in our approach, but we will never lose the "Zorba-like" passion for LIFE that makes our mission so vital. After we watch the movie we will have an employee post-movie session to address and discuss, among others, some relevant SELLAS points: a.) risk & innovation; b.) resilience; c.) passion & analysis; d.) cultural identity; e.) personal responsibility & reflections …of course, as many know, I was born and raised in Germany, thus the disciplined and focused approach is instilled in me and our company.

145

🚀 Vincogen Announces AML-Focused Expansion of Its VincoAI-Generated Therapeutic Pipeline (Yardley, Pennsylvania – November 29, 2025 )— VincoAI Biologics proudly announces a significant expansion of its in silico biologics pipeline with a deep focus on Acute Myeloid Leukemia (AML)—one of the most aggressive and genetically complex blood cancers. Through our VincoAI Peptide Platform and VincoAI VH Nanoantibody Platform, we have generated AI-designed molecules against a broad panel of high-value AML therapeutic targets, including: 🔬 Key AML Targets Now Covered by VincoAI Biologics • CD33 – gold-standard AML surface marker • BCL2 – validated target of venetoclax-based therapy • KIT/CD117 – core-binding factor AML driver • KRAS & KRAS G12C – critical RAS-pathway mutations • CD47 & SIRPα – macrophage immune-evasion axis • PD-1, PD-L1, PD-L2, CTLA4 – AML immune checkpoint targets • LAG3, TIGIT, NKG2A, CD276 – emerging AML immunotherapy nodes • BTK, CDK4, CDK6, EZH2, PARP1, LSD1, HDAC3, WEE1 – essential AML signaling & epigenetic regulators • mTOR, MYC, ERK5, MKK4, JAK3 – AML proliferation and survival pathways Leveraging our proprietary multimodal AI engines, we have launched simultaneous peptide and VH nanoantibody design campaigns to accelerate discovery across immunotherapy, targeted therapy, and leukemia stem-cell biology. ⸻ 🎯 Why AML? AML continues to show: • High relapse rates • Limited targeted options compared to solid tumors • Strong demand for novel biologics addressing immune evasion, metabolic dependencies, and leukemia stem-cell survival VincoAI Biologics aims to address these unmet needs through computationally driven biologics generation, rapid structural optimization, and broad target exploration at unprecedented speed. ⸻ 🧬 Advancing AI-Enabled Hematologic Oncology This AML-focused portfolio expansion reinforces VincoAI’s mission to transform biologics development through scalable, AI-first engineering—unlocking new therapeutic opportunities for patients with limited treatment options. Forward-looking statement: Computational predictions don't guarantee experimental efficacy. Results may vary. 🔬 Please contact Alexander G. Lai at alexl@vincogen.com for more information. 🌐 Follow VincoAI Biologics for upcoming releases on AML-focused candidates, structural datasets, and preclinical nomination milestones.

4

Unified data and smarter launches is the next frontier in pharma strategy. One of Inizio’s sessions at Fierce Pharma Week explores how Commercial and Medical Affairs can collaborate with AI and Analytics to power precision launches. Enabling the optimizing of pivotal moments starts with insightful data as the foundation and then is informed with sound counsel.

15

I’m attending Fierce Pharma Week 2025 from Fierce Life Sciences Events in Philadelphia this week and wanted to share a few highlights from a commercial perspective. Day 1 spotlighted the evolving landscape of pharmaceutical commercialization, the pivotal role of AI, and the deeply human aspects of strategic decision-making. Key Highlights Traditional launch strategies are being replaced with agile, omnichannel, and AI-driven approaches for better customer engagement and market readiness. AI is revolutionizing everything from rare disease forecasting to content generation, with cultural shifts needed to fully harness its potential. AI in healthcare is still exploding with ideas and testing to see what works. Teams are leveraging AI tools—like turning past research interviews into searchable audio files via large language models, and using predictive AI to map out rare disease progression and validate messaging before launch. Real-world forecasting and value-based models are critical, especially in rare diseases where personal stories drive strategy. The most captivating stories are often coupled with the most difficult market and forecast to model. Workshops underscored the importance of clarity, collaboration, and actionable decision-making for effective commercial strategy. Data-driven launch planning and storytelling are now essential, as manufacturing and quality innovations showcase AI’s measurable impact. Human elements matter: Sessions highlighted the “two pizza rule” for better team decisions and the value of early, inclusive cross-functional planning—sometimes tracking 35,000+ individual conversations over years to guide launch and build an unbiased, more well rounded understanding of the market. The week kicked off by blending science, technology, and human insight to redefine how pharma brings value to patients and the market.

40

2 Comments